BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

Four Abstracts On Roche (RHHBY)'s C.E.R.A. Accepted For Presentation At Leading European Nephrology Congress


7/6/2006 3:18:33 PM

NUTLEY, N.J., July 6 /PRNewswire-FirstCall/ -- Nephrologists attending the upcoming 43rd European Renal Association-European Dialysis and Transplant Association (ERA-EDTA) congress in Glasgow, Scotland, July 15-18, will be able to hear a range of study results from Roche's robust clinical development program for its investigational anti-anemia drug, C.E.R.A. (Continuous Erythropoietin Receptor Activator).

Among the highlights will be the first public presentation of data from the C.E.R.A. Phase III clinical development program -- the largest of its kind -- with results from the maintenance studies in dialysis patients.

C.E.R.A. Presentations Author: N. Levin Intravenous (IV) C.E.R.A. (continuous erythropoietin receptor activator) administered once every two weeks or once monthly maintains hemoglobin (Hb) levels in patients with chronic kidney disease(CKD) on Dialysis. Sunday, July 16, 2006 Oral Session: 13:45 - 15:15; Hall 1 Poster ID: SO23 Author: W. Sulowicz Subcutaneous (SC) C.E.R.A. (continuous erythropoietin receptor activator) administered once every two weeks or once monthly maintains hemoglobin (Hb) levels in patients with chronic kidney disease (CKD) on Dialysis. Sunday, July 16, 2006 Poster Session: 08:00 - 16:00; Poster Area, Hall 4 Poster ID: SP424 Author: B. Canaud Intravenous (IV) C.E.R.A. (continuous erythropoietin receptor activator) administered once every two weeks maintains stable hemoglobin (Hb) levels in patients with chronic kidney disease (CKD) on dialysis. Sunday, July 16, 2006 Poster Session: 08:00 - 16:00; Poster Area, Hall 4 Poster ID: SP425 Author: M. Brandt Different receptor binding activity of C.E.R.A. (continuous erythropoietin receptor activator) compared with epoetin beta determined by surface plasmon resonance and competition assay on UT-7 cells. Sunday, July 16, 2006 Oral Session: 13:45 - 15:15; Hall 1 Poster ID: SO18

Interested journalists may view the titles of ERA-EDTA abstracts selected for presentation, as well as the meeting schedule online at http://www.eraedta2006.org/fp2006.htm .

Roche

CONTACT: Shelley Rosenstock, Roche, +1-973-562-2373,shelley.rosenstock@roche.com; Diana Scott, MS&L, +1-212-468-4271,diana.scott@mslpr.com



Read at BioSpace.com

   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES